Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe , a multicentric, observational study.
The study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the study. Methodological differences between the two studies impose significant limits to comparability concerning effectiveness, and strongly invite further research.
